Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Objective Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to invest...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 75; no. 1; pp. 84 - 97 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston, USA
Wiley Periodicals, Inc
01.01.2023
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 2326-5191 2326-5205 2326-5205 |
DOI | 10.1002/art.42321 |
Cover
Abstract | Objective
Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA‐induced myeloid cell activation and vasculitis pathogenesis.
Methods
Phosphorylation of Syk in myeloid cells from healthy controls and ANCA‐associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)–ANCA IgG activation of cells was investigated using functional assays (interleukin‐8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.
Results
We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO‐ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA‐mediated cellular responses. Using targeted gene expression analysis, we identified up‐regulation of FcR‐ and Syk‐dependent signaling pathways following MPO‐ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.
Conclusion
These findings indicate that Syk plays a critical role in MPO‐ANCA IgG–induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option. |
---|---|
AbstractList | Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG-mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA-induced myeloid cell activation and vasculitis pathogenesis.
Phosphorylation of Syk in myeloid cells from healthy controls and ANCA-associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)-ANCA IgG activation of cells was investigated using functional assays (interleukin-8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.
We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO-ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA-mediated cellular responses. Using targeted gene expression analysis, we identified up-regulation of FcR- and Syk-dependent signaling pathways following MPO-ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.
These findings indicate that Syk plays a critical role in MPO-ANCA IgG-induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option. Objective Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA‐induced myeloid cell activation and vasculitis pathogenesis. Methods Phosphorylation of Syk in myeloid cells from healthy controls and ANCA‐associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)–ANCA IgG activation of cells was investigated using functional assays (interleukin‐8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization. Results We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO‐ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA‐mediated cellular responses. Using targeted gene expression analysis, we identified up‐regulation of FcR‐ and Syk‐dependent signaling pathways following MPO‐ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV. Conclusion These findings indicate that Syk plays a critical role in MPO‐ANCA IgG–induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option. ObjectiveSyk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG–mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA‐induced myeloid cell activation and vasculitis pathogenesis.MethodsPhosphorylation of Syk in myeloid cells from healthy controls and ANCA‐associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)–ANCA IgG activation of cells was investigated using functional assays (interleukin‐8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.ResultsWe identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO‐ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA‐mediated cellular responses. Using targeted gene expression analysis, we identified up‐regulation of FcR‐ and Syk‐dependent signaling pathways following MPO‐ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.ConclusionThese findings indicate that Syk plays a critical role in MPO‐ANCA IgG–induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option. Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG-mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA-induced myeloid cell activation and vasculitis pathogenesis.OBJECTIVESyk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought to be important in antineutrophil cytoplasm antibody (ANCA) IgG-mediated neutrophil activation. This study was undertaken to investigate the role of Syk in ANCA-induced myeloid cell activation and vasculitis pathogenesis.Phosphorylation of Syk in myeloid cells from healthy controls and ANCA-associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)-ANCA IgG activation of cells was investigated using functional assays (interleukin-8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.METHODSPhosphorylation of Syk in myeloid cells from healthy controls and ANCA-associated vasculitis (AAV) patients was analyzed using flow cytometry. The effect of Syk inhibition on myeloperoxidase (MPO)-ANCA IgG activation of cells was investigated using functional assays (interleukin-8 and reactive oxygen species production) and targeted gene analysis with NanoString. Total and phosphorylated Syk at sites of tissue inflammation in patients with AAV was assessed using immunohistochemistry and RNAscope in situ hybridization.We identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO-ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA-mediated cellular responses. Using targeted gene expression analysis, we identified up-regulation of FcR- and Syk-dependent signaling pathways following MPO-ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.RESULTSWe identified increased phosphorylated Syk at critical activatory tyrosine residues in blood neutrophils and monocytes from patients with active AAV compared to patients with disease in remission or healthy controls. Syk was phosphorylated in vitro following MPO-ANCA IgG stimulation, and Syk inhibition was able to prevent ANCA-mediated cellular responses. Using targeted gene expression analysis, we identified up-regulation of FcR- and Syk-dependent signaling pathways following MPO-ANCA IgG stimulation. Finally, we showed that Syk is expressed and phosphorylated in tissue leukocytes at sites of organ inflammation in AAV.These findings indicate that Syk plays a critical role in MPO-ANCA IgG-induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option.CONCLUSIONThese findings indicate that Syk plays a critical role in MPO-ANCA IgG-induced myeloid cell responses and that Syk is activated in circulating immune cells and tissue immune cells in AAV; therefore, Syk inhibition may be a potential therapeutic option. |
Author | McAdoo, Stephen P. Bhatt, Tejal Prendecki, Maria Tam, Frederick W. K. Pisacano, Noelle Masuda, Esteban S. Mawhin, Marie‐Anne Roufosse, Candice Pinheiro, Damilola Lodge, Katharine M. Pusey, Charles D. Gulati, Kavita Toulza, Frederic Cowburn, Andrew |
AuthorAffiliation | 1 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital London UK 2 National Heart and Lung Institute, Imperial College London UK 4 Rigel Pharmaceuticals South San Francisco California 3 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London Hammersmith Campus London UK |
AuthorAffiliation_xml | – name: 3 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London Hammersmith Campus London UK – name: 4 Rigel Pharmaceuticals South San Francisco California – name: 1 Department of Immunology and Inflammation Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital London UK – name: 2 National Heart and Lung Institute, Imperial College London UK |
Author_xml | – sequence: 1 givenname: Maria orcidid: 0000-0001-7048-7457 surname: Prendecki fullname: Prendecki, Maria email: m.prendecki@imperial.ac.uk organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital – sequence: 2 givenname: Kavita orcidid: 0000-0002-2651-593X surname: Gulati fullname: Gulati, Kavita organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital – sequence: 3 givenname: Noelle surname: Pisacano fullname: Pisacano, Noelle organization: National Heart and Lung Institute, Imperial College – sequence: 4 givenname: Damilola surname: Pinheiro fullname: Pinheiro, Damilola organization: Centre for Inflammatory Disease, Imperial College London – sequence: 5 givenname: Tejal surname: Bhatt fullname: Bhatt, Tejal organization: Centre for Inflammatory Disease, Imperial College London – sequence: 6 givenname: Marie‐Anne surname: Mawhin fullname: Mawhin, Marie‐Anne organization: Centre for Inflammatory Disease, Imperial College London – sequence: 7 givenname: Frederic surname: Toulza fullname: Toulza, Frederic organization: Centre for Inflammatory Disease, Imperial College London – sequence: 8 givenname: Esteban S. surname: Masuda fullname: Masuda, Esteban S. organization: Rigel Pharmaceuticals – sequence: 9 givenname: Andrew surname: Cowburn fullname: Cowburn, Andrew organization: National Heart and Lung Institute, Imperial College – sequence: 10 givenname: Katharine M. surname: Lodge fullname: Lodge, Katharine M. organization: National Heart and Lung Institute, Imperial College – sequence: 11 givenname: Frederick W. K. surname: Tam fullname: Tam, Frederick W. K. organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital – sequence: 12 givenname: Candice surname: Roufosse fullname: Roufosse, Candice organization: Centre for Inflammatory Disease, Imperial College London – sequence: 13 givenname: Charles D. surname: Pusey fullname: Pusey, Charles D. organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital – sequence: 14 givenname: Stephen P. orcidid: 0000-0001-8260-8770 surname: McAdoo fullname: McAdoo, Stephen P. organization: Centre for Inflammatory Disease, Imperial College London, Hammersmith Campus, and Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36428281$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kcFu1DAQhi1URMvSAy-AInGhh21tx3biE4oiCpUqIcHC1fI6TuuS2IvtFEVceAfekCdhuttWUAl8GVv-5tc_8z9Fez54i9Bzgo8JxvREx3zMaEnJI3QARSw5xXzv7k4k2UeHKV1hOLLCAvMnaL8UjNa0Jgfo-8f5S9GY7K51dsEXzheti2Ya4OkvCu27YuVSmmxx5r3OUMZx8rZo7TCkG7rxANopx7C5dEPRzjlsBp1GZ7Zf69DNv378bFIKxkF_V3zWCeRddukZetzrIdnD27pAn07frNp3y_P3b8_a5nxpOMFk2fe4FlILxqUglgtWUVxKjsveGGIFrYWu1nhtGCtLU1sjOhhNYlFhZrpKynKBXu90N9N6tJ2xPkc9qE10o46zCtqpv3-8u1QX4VrBfqWsMQeFV7cKMXydbMpqdMnACrS3YUqKVgyDIQYWFujlA_QqTNHDfEDxmmPGtpZe_Gnp3stdMAAc7QATQ0rR9vcIwTe-qILc1TZ3YE8esMblbZwwjRv-1_HNDXb-t7RqPqx2Hb8BAE2_2g |
CitedBy_id | crossref_primary_10_1093_rheumatology_keae566 crossref_primary_10_1186_s13075_023_03201_9 crossref_primary_10_3389_fphar_2023_1056154 crossref_primary_10_3389_fimmu_2023_1261151 crossref_primary_10_1016_j_heliyon_2023_e15625 crossref_primary_10_1016_j_imlet_2024_106933 |
Cites_doi | 10.1016/j.bbamcr.2009.03.004 10.1681/ASN.2010050477 10.1002/path.5746 10.1016/S1074-7613(01)00150-9 10.1084/jem.20081859 10.1016/j.kint.2019.12.014 10.1093/nar/gkv007 10.1097/01.ASN.0000113241.98702.77 10.1074/jbc.RA119.008045 10.2215/CJN.11501114 10.1038/nbt.1990 10.1084/jem.186.7.1027 10.1002/1529-0131(200107)44:7<1698::AID-ART294>3.0.CO;2-J 10.1124/jpet.106.109058 10.1111/cei.12625 10.1111/imr.12455 10.1038/nri840 10.1046/j.1523-1755.1999.055003852.x 10.1056/NEJMoa0909169 10.1073/pnas.87.11.4115 10.4049/jimmunol.131.1.140 10.1016/j.immuni.2012.11.015 10.1056/NEJMoa1000500 10.1016/j.jmb.2012.11.007 10.1016/S0167-5699(99)01574-1 10.1681/ASN.V83386 10.1046/j.1523-1755.2000.057003846.x 10.1182/blood-2010-12-326355 10.1038/nri2765 10.1074/jbc.274.20.14229 10.1093/nar/gkv468 10.1016/S0021-9258(20)80545-6 10.1002/ajh.25125 10.1128/MCB.18.7.4209 10.1002/art.23757 10.1111/j.1365-2249.1994.tb06137.x 10.4049/jimmunol.153.3.1271 10.1074/jbc.M806340200 10.1681/ASN.2009030263 10.1038/ki.2015.29 10.4049/jimmunol.161.12.6909 10.1002/prp2.175 10.1074/jbc.271.18.10775 10.1681/ASN.2013090978 10.1172/JCI119662 |
ContentType | Journal Article |
Copyright | 2022 The Authors. published by Wiley Periodicals LLC on behalf of American College of Rheumatology. 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. 2022. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2022 The Authors. published by Wiley Periodicals LLC on behalf of American College of Rheumatology. – notice: 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. – notice: 2022. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 C1K H94 K9. 7X8 5PM |
DOI | 10.1002/art.42321 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Bacteriology Abstracts (Microbiology B) Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE Toxicology Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | SYK ACTIVATION IN ANCA‐ASSOCIATED VASCULITIS |
EISSN | 2326-5205 |
EndPage | 97 |
ExternalDocumentID | PMC10099805 36428281 10_1002_art_42321 ART42321 |
Genre | researchArticle Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Academy of Medical Sciences funderid: SGL023/1071 – fundername: Vasculitis UK – fundername: ; – fundername: ; grantid: SGL023/1071 |
GroupedDBID | 0R~ 1OC 24P 33P 3SF 4.4 52O 52U 52V 53G 5VS AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAQQT AASGY AAWTL AAXRX AAYCA AAZKR ABCUV ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACRPL ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 DCZOG DIK DRFUL DRMAN DRSTM EBS EJD EMOBN EX3 F00 FUBAC G-S G.N GODZA HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM NF~ O66 O9- OK1 OVD P2W PQQKQ QB0 ROL SUPJJ SV3 TEORI V9Y WBKPD WHWMO WIH WIJ WIK WOHZO WVDHM WXSBR YCJ AAFWJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QL 7QP 7T5 7TM 7U7 AAMMB AEFGJ AGXDD AIDQK AIDYY C1K H94 K9. 7X8 5PM |
ID | FETCH-LOGICAL-c5101-ff0869a645961e56472039503fcc1e6286a7b0bc4433c8ec6d828906704cd7993 |
IEDL.DBID | 24P |
ISSN | 2326-5191 2326-5205 |
IngestDate | Thu Aug 21 18:38:16 EDT 2025 Fri Jul 11 02:49:20 EDT 2025 Fri Jul 25 12:08:15 EDT 2025 Thu Apr 03 07:06:55 EDT 2025 Tue Jul 01 00:56:06 EDT 2025 Thu Apr 24 23:02:51 EDT 2025 Wed Jan 22 16:21:36 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Attribution-NonCommercial 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5101-ff0869a645961e56472039503fcc1e6286a7b0bc4433c8ec6d828906704cd7993 |
Notes | Supported by the NIHR Imperial Biomedical Research Centre. Dr. Prendecki's work was supported by the Academy of Medical Sciences (grant SGL023/1071) and by an NIHR Clinical Lectureship. Dr. Tam's work was supported by the Ken and Mary Minton Chair of Renal Medicine. Dr. McAdoo's work was supported by Vasculitis UK and by an Imperial College Wellcome Trust ISSF Fellowship. https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42321&file=art42321‐sup‐0001‐Disclosureform.pdf Presented in abstract form at the 19th International Vasculitis and ANCA Workshop in Philadelphia, PA, in April 2019 . Author disclosures are available at https://doi.org/10.1093/rheumatology/kez061.027 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Author disclosures are available at https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42321&file=art42321‐sup‐0001‐Disclosureform.pdf. Presented in abstract form at the 19th International Vasculitis and ANCA Workshop in Philadelphia, PA, in April 2019 (https://doi.org/10.1093/rheumatology/kez061.027). |
ORCID | 0000-0002-2651-593X 0000-0001-7048-7457 0000-0001-8260-8770 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.42321 |
PMID | 36428281 |
PQID | 2758504499 |
PQPubID | 946334 |
PageCount | 14 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10099805 proquest_miscellaneous_2740503444 proquest_journals_2758504499 pubmed_primary_36428281 crossref_primary_10_1002_art_42321 crossref_citationtrail_10_1002_art_42321 wiley_primary_10_1002_art_42321_ART42321 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | January 2023 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 01 year: 2023 text: January 2023 |
PublicationDecade | 2020 |
PublicationPlace | Boston, USA |
PublicationPlace_xml | – name: Boston, USA – name: United States – name: Atlanta |
PublicationTitle | Arthritis & rheumatology (Hoboken, N.J.) |
PublicationTitleAlternate | Arthritis Rheumatol |
PublicationYear | 2023 |
Publisher | Wiley Periodicals, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Periodicals, Inc – name: Wiley Subscription Services, Inc |
References | 2010; 10 2015; 181 2011; 118 2006; 319 2015; 3 1983; 131 2000; 21 1994; 153 2013; 425 2015; 10 2008; 58 2010; 363 2002; 2 2014; 25 2001; 44 1993; 268 1993; 1 2008; 283 1997; 8 1998; 18 2010; 21 1990; 87 2013; 38 2020; 97 2021; 255 2000; 57 1997; 186 2004; 15 2015; 88 1997; 100 2015; 43 1999; 274 1996; 271 1999; 55 2018; 93 2019; 294 2009; 206 2001; 14 2011; 29 2009; 1793 2016; 273 1998; 161 1994; 98 e_1_2_7_6_1 Savage CO (e_1_2_7_13_1) 1993; 1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_42_1 e_1_2_7_43_1 e_1_2_7_12_1 e_1_2_7_44_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_47_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Porges AJ (e_1_2_7_14_1) 1994; 153 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 Kurlander RJ (e_1_2_7_38_1) 1983; 131 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_39_1 |
References_xml | – volume: 319 start-page: 998 year: 2006 article-title: R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex‐mediated inflammation publication-title: J Pharmacol Exp Ther – volume: 98 start-page: 270 year: 1994 end-page: 8 article-title: Activation of granulocytes by anti‐neutrophil cytoplasmic antibodies (ANCA): a Fc γ RII‐dependent process publication-title: Clin Exp Immunol – volume: 25 start-page: 2291 year: 2014 end-page: 302 article-title: Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN publication-title: J Am Soc Nephrol – volume: 21 start-page: 1628 year: 2010 article-title: Histopathologic classification of ANCA‐associated glomerulonephritis publication-title: J Am Soc Nephrol – volume: 186 start-page: 1027 year: 1997 end-page: 39 article-title: A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages publication-title: J Exp Med – volume: 206 start-page: 577 year: 2009 end-page: 93 article-title: Critical role of phospholipase Cγ2 in integrin and Fc receptor‐mediated neutrophil functions and the effector phase of autoimmune arthritis publication-title: J Exp Med – volume: 44 start-page: 1698 year: 2001 end-page: 706 article-title: Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro publication-title: Arthritis Rheum – volume: 57 start-page: 846 year: 2000 end-page: 62 article-title: Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features publication-title: Kidney Int – volume: 181 start-page: 65 year: 2015 end-page: 75 article-title: CD14 expression is increased on monocytes in patients with anti‐neutrophil cytoplasm antibody (ANCA)‐associated vasculitis and correlates with the expression of ANCA autoantigens publication-title: Clin Exp Immunol – volume: 38 start-page: 475 year: 2013 end-page: 88 article-title: The BAFF receptor transduces survival signals by co‐opting the B cell receptor signaling pathway publication-title: Immunity – volume: 153 start-page: 1271 year: 1994 end-page: 80 article-title: Anti‐neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc γ RIIa publication-title: J Immunol (Baltimore) – volume: 100 start-page: 1416 year: 1997 end-page: 24 article-title: Antineutrophil cytoplasmic antibodies induce monocyte IL‐8 release. Role of surface proteinase‐3, α1‐antitrypsin, and Fcγ receptors publication-title: J Clin Invest – volume: 1 start-page: 190 year: 1993 end-page: 5 article-title: Anti‐neutrophil cytoplasm antibodies can recognize vascular endothelial cell‐bound anti‐neutrophil cytoplasm antibody‐associated autoantigens publication-title: Exp Nephrol – volume: 283 start-page: 32650 year: 2008 end-page: 9 article-title: Molecular mechanism of the Syk activation switch publication-title: J Biol Chem – volume: 15 start-page: 796 year: 2004 end-page: 808 article-title: Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcγ receptors and CD18 publication-title: J Am Soc Nephrol – volume: 93 start-page: 921 year: 2018 end-page: 30 article-title: Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo‐controlled trials publication-title: Am J Hematol – volume: 3 year: 2015 article-title: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib publication-title: Pharmacol Res Perspect – volume: 14 start-page: 693 year: 2001 end-page: 704 article-title: Fc γ RIII mediates neutrophil recruitment to immune complexes. A mechanism for neutrophil accumulation in immune‐mediated inflammation publication-title: Immunity – volume: 21 start-page: 148 year: 2000 end-page: 54 article-title: Tyrosine kinase Syk: essential functions for immunoreceptor signalling publication-title: Immunol Today – volume: 425 start-page: 309 year: 2013 end-page: 33 article-title: Structural and biophysical characterization of the Syk activation switch publication-title: J Mol Biol – volume: 97 start-page: 1196 year: 2020 end-page: 207 article-title: Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre‐clinical model publication-title: Kidney Int – volume: 255 start-page: 107 year: 2021 end-page: 19 article-title: Characterisation of an enhanced preclinical model of experimental MPO‐ANCA autoimmune vasculitis publication-title: J Pathol – volume: 274 start-page: 14229 year: 1999 end-page: 37 article-title: Tyrosine 319 in the interdomain B of ZAP‐70 is a binding site for the Src homology 2 domain of Lck publication-title: J Biol Chem – volume: 58 start-page: 2712 year: 2008 end-page: 22 article-title: Vav/Phospholipase Cγ2–mediated control of a neutrophil‐dependent murine model of rheumatoid arthritis publication-title: Arthritis Rheum – volume: 268 start-page: 24442 year: 1993 end-page: 8 article-title: Cross‐linking of Fc γ receptor I (Fc γ RI) and receptor II (Fc γ RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase publication-title: J Biol Chem – volume: 88 start-page: 52 year: 2015 end-page: 60 article-title: Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression publication-title: Kidney Int – volume: 1793 start-page: 1115 year: 2009 end-page: 27 article-title: Syk and pTyr'd: signaling through the B cell antigen receptor [review] publication-title: Biochim Biophys Acta – volume: 43 year: 2015 article-title: Limma powers differential expression analyses for RNA‐sequencing and microarray studies publication-title: Nucleic Acids Res – volume: 8 start-page: 386 year: 1997 end-page: 94 article-title: Crosslinking of ANCA‐antigens stimulates superoxide release by human neutrophils publication-title: J Am Soc Nephrol – volume: 18 start-page: 4209 year: 1998 end-page: 20 article-title: The Syk protein tyrosine kinase is essential for Fcγ receptor signaling in macrophages and neutrophils publication-title: Mol Cell Biol – volume: 2 start-page: 476 year: 2002 end-page: 86 article-title: VAV proteins as signal integrators for multi‐subunit immune‐recognition receptors [review] publication-title: Nat Rev Immunol – volume: 271 start-page: 10775 year: 1996 end-page: 81 article-title: Phosphoinositide 3‐kinase and p72syk noncovalently associate with the low affinity Fc γ receptor on human platelets through an immunoreceptor tyrosine‐based activation motif. Reconstitution with synthetic phosphopeptides publication-title: J Biol Chem – volume: 161 start-page: 6909 year: 1998 end-page: 14 article-title: Antineutrophil cytoplasmic antibodies preferentially engage Fc γRIIIb on human neutrophils publication-title: J Immunol (Baltimore) – volume: 10 start-page: 4 year: 2015 end-page: 6 article-title: ANCAs are also antimonocyte cytoplasmic autoantibodies publication-title: Clin J Am Soc Nephrol – volume: 55 start-page: 852 year: 1999 end-page: 63 article-title: Interleukin‐8: a pathogenetic role in antineutrophil cytoplasmic autoantibody‐associated glomerulonephritis publication-title: Kidney Int – volume: 131 start-page: 140 year: 1983 end-page: 7 article-title: Blockade of Fc receptor‐mediated binding to U‐937 cells by murine monoclonal antibodies directed against a variety of surface antigens publication-title: J Immunol (Baltimore) – volume: 294 start-page: 7658 year: 2019 end-page: 68 article-title: A reevaluation of the spleen tyrosine kinase (Syk) activation mechanism publication-title: J Biol Chem – volume: 43 start-page: W566 year: 2015 end-page: 70 article-title: ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap publication-title: Nucleic Acids Res – volume: 10 start-page: 387 year: 2010 end-page: 402 article-title: The Syk tyrosine kinase: a crucial player in diverse biological functions [review] publication-title: Nat Rev Immunol – volume: 118 start-page: e16 year: 2011 end-page: 31 article-title: Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets publication-title: Blood – volume: 363 start-page: 211 year: 2010 end-page: 20 article-title: Rituximab versus Cyclophosphamide in ANCA‐associated renal vasculitis publication-title: New Engl J Med – volume: 29 start-page: 1046 year: 2011 end-page: 51 article-title: Comprehensive analysis of kinase inhibitor selectivity publication-title: Nat Biotech – volume: 21 start-page: 231 year: 2010 end-page: 6 article-title: A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis publication-title: J Am Soc Nephrol – volume: 273 start-page: 121 year: 2016 end-page: 39 article-title: Tyrosine kinase signaling pathways in neutrophils [review] publication-title: Immunol Rev – volume: 363 start-page: 1303 year: 2010 end-page: 12 article-title: An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis publication-title: New Engl J Med – volume: 87 start-page: 4115 year: 1990 end-page: 9 article-title: Anti‐neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro publication-title: Proc Natl Acad Sci U S A – volume: 1 start-page: 190 year: 1993 ident: e_1_2_7_13_1 article-title: Anti‐neutrophil cytoplasm antibodies can recognize vascular endothelial cell‐bound anti‐neutrophil cytoplasm antibody‐associated autoantigens publication-title: Exp Nephrol – ident: e_1_2_7_5_1 doi: 10.1016/j.bbamcr.2009.03.004 – ident: e_1_2_7_30_1 doi: 10.1681/ASN.2010050477 – ident: e_1_2_7_47_1 doi: 10.1002/path.5746 – ident: e_1_2_7_34_1 doi: 10.1016/S1074-7613(01)00150-9 – ident: e_1_2_7_39_1 doi: 10.1084/jem.20081859 – ident: e_1_2_7_22_1 doi: 10.1016/j.kint.2019.12.014 – ident: e_1_2_7_24_1 doi: 10.1093/nar/gkv007 – ident: e_1_2_7_19_1 doi: 10.1097/01.ASN.0000113241.98702.77 – ident: e_1_2_7_11_1 doi: 10.1074/jbc.RA119.008045 – ident: e_1_2_7_26_1 doi: 10.2215/CJN.11501114 – ident: e_1_2_7_43_1 doi: 10.1038/nbt.1990 – ident: e_1_2_7_3_1 doi: 10.1084/jem.186.7.1027 – ident: e_1_2_7_16_1 doi: 10.1002/1529-0131(200107)44:7<1698::AID-ART294>3.0.CO;2-J – ident: e_1_2_7_25_1 doi: 10.1124/jpet.106.109058 – ident: e_1_2_7_27_1 doi: 10.1111/cei.12625 – ident: e_1_2_7_8_1 doi: 10.1111/imr.12455 – ident: e_1_2_7_29_1 doi: 10.1038/nri840 – ident: e_1_2_7_37_1 doi: 10.1046/j.1523-1755.1999.055003852.x – ident: e_1_2_7_46_1 doi: 10.1056/NEJMoa0909169 – ident: e_1_2_7_12_1 doi: 10.1073/pnas.87.11.4115 – volume: 131 start-page: 140 year: 1983 ident: e_1_2_7_38_1 article-title: Blockade of Fc receptor‐mediated binding to U‐937 cells by murine monoclonal antibodies directed against a variety of surface antigens publication-title: J Immunol (Baltimore) doi: 10.4049/jimmunol.131.1.140 – ident: e_1_2_7_45_1 doi: 10.1016/j.immuni.2012.11.015 – ident: e_1_2_7_41_1 doi: 10.1056/NEJMoa1000500 – ident: e_1_2_7_9_1 doi: 10.1016/j.jmb.2012.11.007 – ident: e_1_2_7_7_1 doi: 10.1016/S0167-5699(99)01574-1 – ident: e_1_2_7_35_1 doi: 10.1681/ASN.V83386 – ident: e_1_2_7_32_1 doi: 10.1046/j.1523-1755.2000.057003846.x – ident: e_1_2_7_28_1 doi: 10.1182/blood-2010-12-326355 – ident: e_1_2_7_2_1 doi: 10.1038/nri2765 – ident: e_1_2_7_10_1 doi: 10.1074/jbc.274.20.14229 – ident: e_1_2_7_23_1 doi: 10.1093/nar/gkv468 – ident: e_1_2_7_33_1 doi: 10.1016/S0021-9258(20)80545-6 – ident: e_1_2_7_42_1 doi: 10.1002/ajh.25125 – ident: e_1_2_7_4_1 doi: 10.1128/MCB.18.7.4209 – ident: e_1_2_7_40_1 doi: 10.1002/art.23757 – ident: e_1_2_7_17_1 doi: 10.1111/j.1365-2249.1994.tb06137.x – volume: 153 start-page: 1271 year: 1994 ident: e_1_2_7_14_1 article-title: Anti‐neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc γ RIIa publication-title: J Immunol (Baltimore) doi: 10.4049/jimmunol.153.3.1271 – ident: e_1_2_7_6_1 doi: 10.1074/jbc.M806340200 – ident: e_1_2_7_20_1 doi: 10.1681/ASN.2009030263 – ident: e_1_2_7_31_1 doi: 10.1038/ki.2015.29 – ident: e_1_2_7_15_1 doi: 10.4049/jimmunol.161.12.6909 – ident: e_1_2_7_44_1 doi: 10.1002/prp2.175 – ident: e_1_2_7_18_1 doi: 10.1074/jbc.271.18.10775 – ident: e_1_2_7_21_1 doi: 10.1681/ASN.2013090978 – ident: e_1_2_7_36_1 doi: 10.1172/JCI119662 |
SSID | ssj0000970605 |
Score | 2.4574478 |
Snippet | Objective
Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk... Syk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is thought... ObjectiveSyk is a cytoplasmic protein tyrosine kinase that plays a role in signaling via B cell and Fc receptors (FcR). FcR engagement and signaling via Syk is... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 84 |
SubjectTerms | Activation analysis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antibodies, Antineutrophil Cytoplasmic Antineutrophil cytoplasmic antibodies Cell activation Cytoplasm Fc receptors Flow cytometry Full Length Gene expression Humans Hybridization Immune system Immunity, Innate Immunoglobulin G Immunohistochemistry Inflammation Interleukins Kinases Leukocytes Leukocytes (neutrophilic) Monocytes Myeloid cells Pathogenesis Peroxidase Phosphorylation Protein-tyrosine kinase Reactive oxygen species Receptors, Fc Remission Signaling Stimulation Syk Kinase Syk protein Tissues Tyrosine Vasculitis |
Title | Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.42321 https://www.ncbi.nlm.nih.gov/pubmed/36428281 https://www.proquest.com/docview/2758504499 https://www.proquest.com/docview/2740503444 https://pubmed.ncbi.nlm.nih.gov/PMC10099805 |
Volume | 75 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2326-5205 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0000970605 issn: 2326-5191 databaseCode: DIK dateStart: 19990101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LTttAFB0hKqFuKlpoG0rRULHoxo0fY8cWqygUJSAqJKDKzppXiIUZR3ksom74B_6QL-m94wdEoVI3kaW5cZy5vp5zZjznEHLEgfZEPFCOiGLlMA25EJ6QjgiiSGogzsIKmF78ivo37GwYDjfIcb0XptSHaCbcsDLs8xoLnItZ-1k0FHr2B64yAvV54-Goj7LO7LKZYHETFIYJrbmcHzmAVLxaWcj12823V8ejNZC5_q7kSwxrB6HTbfKuQo-0W6b7PdnQ5gPZuqjWx3fIn6vlHe3K2rKMZob2sqm0Fl3mlnKj6LXtaTowBlAmHeD2EE17Os9nGN1F4wi9mE-LyTjLaW85LyaAr-8zaZtEoZZPD491TrWiv-2brCiMtEtuTn9e9_pOZa_gSCxEZzQCOpNwVJOJPB2ijrwbJKEbjKT0NG5Z5R3hCslYEMhYy0ghO8N9PUyqDuCaj2TTFEZ_JpRDD2sVKxEnmiVwUvT_BWKFPh5c6aRFvtednMpKexwtMPK0VE32U8hHavPRIt-a0EkpuPFa0H6dqbSquVnqI_VxGVC4FjlsmqFacAmEG10sMIahAA5jrEU-lYltfiVAKubHcPJ4JeVNACpxr7aYbGwVuT0E2rEbwv-0d8e_rzwFmmIP9v4_9At5iyb35cTPPtmcTxf6K0ChuTiwtzx8ngzO_wI4hAcA |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LbtNAFL2qWgnYoJYCTV8MFQs2pn6Mp7bEJopaJdBUSKSoO8vzSGs1jKM0WURs-If-Yb-Ee8cPiAoSO0tzYztz59rnzHjOAXiXI-0ReaQ9KRLtcYO5kIFUnoyEUAaJs3QCpsML0b_kn67iqzX42OyFqfQh2gk3qgz3vKYCpwnp49-qodi1H2iZEbnPBhehT2M65F_aGRY_JWWY2LnLhcJDqBI00kJ-eNz-evWF9AhlPv5Y8k8Q695CZ5vwvIaPrFvlewvWjH0BT4b1Avk2_Pi6vGVd1XiWscKyXjFTzqPLXrPcajZyXc0G1iLMZAPaH2JYz0wmdxTdJecIs5jPyulNMWG95bycIsD-XijXJEu9fPh53yTVaPbNfcpKykgv4fLsdNTre7W_gqeoEr3xGPlMmpOcjAhMTELyfpTGfjRWKjC0ZzU_kb5UnEeRSowSmugZbezhSp8gsHkF67a0ZgdYjj1sdKJlkhqe4knJABiZFRl55NqkHXjfdHKmavFx8sCYZJVscphhPjKXjw4ctaHTSnHjb0H7TaayuujuspC4j8-Rw3XgbduM5UJrILk15YJiOCngcM478LpKbHuViLhYmODJk5WUtwEkxb3aYosbJ8kdENJO_Bj_pxsd_77zDHmKO9j9_9A38LQ_Gp5n54OLz3vwjBzvq1mgfVifzxbmAHHRXB664f8LOV8Jdg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LTttAFL1CICE2qDybQssUdcHG4MfY2GIVBSLSFoRUQOwszyNgEcZRSBZRN_0H_rBf0nvHD4igEjtLc_2a62ufM-M5B-BbhrQnygLliChWDteYC-EJ6YggiqRG4iysgOnZeXR6xb_fhDdzcFSvhSn1IZoBN6oM-76mAh-q_sGzaCj27D7NMiL1WeAk2UKyzvyiGWBxExKGCa25nB85iFS8WlnI9Q-avWe_R69A5ut_JV9iWPsR6n6A5Qo9snaZ7hWY02YVFs-q-fE1-P1res_asrYsY7lhnXwkrUWXuWWZUezS9jTrGYMok_VoeYhmHT0YPFJ0m4wj9GQ8KoZ3-YB1puNiiPj6IZe2SRRq-vfPU51Trdi1_ZOVhJHW4ap7ctk5dSp7BUdSITr9PtKZJCM1mcjTIenIu0ESukFfSk_TktXsULhCch4EMtYyUsTOaF0Pl-oQcc0GzJvC6I_AMuxhrWIl4kTzBA9K_r9IrMjHI1M6acFe3cmprLTHyQJjkJaqyX6K-UhtPlqw24QOS8GNt4K260ylVc09pj5RH5cjhWvB16YZq4WmQDKjiwnFcBLA4Zy3YLNMbHOWgKiYH-PB45mUNwGkxD3bYvI7q8jtEdCO3RDv0z4d_7_yFGmK3fj0_tAdWLw47qY_e-c_tmCJ_O7LMaBtmB-PJvozoqKx-GKf_n-orAio |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Syk+Activation+in+Circulating+and+Tissue+Innate+Immune+Cells+in+Antineutrophil+Cytoplasmic+Antibody-Associated+Vasculitis&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Prendecki%2C+Maria&rft.au=Gulati%2C+Kavita&rft.au=Pisacano%2C+Noelle&rft.au=Pinheiro%2C+Damilola&rft.date=2023-01-01&rft.eissn=2326-5205&rft.volume=75&rft.issue=1&rft.spage=84&rft_id=info:doi/10.1002%2Fart.42321&rft_id=info%3Apmid%2F36428281&rft.externalDocID=36428281 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon |